Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02606305
Recruitment Status : Completed
First Posted : November 17, 2015
Last Update Posted : December 17, 2021
Information provided by (Responsible Party):
ImmunoGen, Inc.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : March 12, 2021
Actual Study Completion Date : March 12, 2021
Certification/Extension First Submitted : December 13, 2021